Graham tells FDA to pull 'toxic' Ketek from market

Share this article:
FDA drug safety expert, whistleblower Dr. David Graham, has called on FDA officials to pull from the market Sanofi-Aventis' controversial antibiotic Ketek, saying it is as toxic, "if not more so," as three other drugs [Rezulin, Trovan and Duract] pulled from the market for liver problems. The FDA has already revised Ketek's labeling.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.